TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00245856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin sodium injection
Description: 200units/kg subcutaneous daily for one month, followed by 150units/kg subcutaneous daily for two additional months or 200 units/kg subcutaneously daily for 5 days followed by warfarin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Titrated to INR 2-3 through study month 3
Study: NCT03450681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency of the saphenous nerve before knee replacement surgery
Description: A trained anesthesiologist and pain clinician performs ultrasound guided pulsed radiofrequency on the saphenous nerve of a patient undergoing knee replacement surgery, prior to the beginning of the surgical act.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Mock incision
Description: A trained anesthesiologist and pain clinician performs a mock incision on the pulsed radiofrequency needle insertion site
Study: NCT02611544

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: 6-week ACT intervention group (n=33)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survivorship Education
Description: 6-week survivorship education group (SE; n=32)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: enhanced usual care (EUC; n=26)
Study: NCT04240990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Development of a score and algorithm for TB treatment decision in hospitalised children with SAM.
Description: The diagnostic strategy will include an initial clinical, radiographic and bacteriological evaluation of all enrolled children:~* TB contact history~* Suggestive TB symptoms in the previous 4 weeks~* Physical examination~* Clinical, anthropometric and biochemical assessment of malnutrition~* Clinical assessment for other non-dietary causes of malnutrition~* Digitalized CXR~* Ultra performed on NPA and stool samples, and one gastric aspirate (GA)~* Mycobacterial culture performed on two GAs~* Abdominal ultrasonography~* QuantiFERON®-TB Gold IGRA~* Monocyte-to-Lymphocyte Ratio (MLR)~* C-Reactive Protein (CRP)~TB diagnosis will be made according to national TB guidelines.
Study: NCT03758027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARESS
Description: The goals of each component are as follows:~* Communicate alternatively - a method to bring the brain back and remove the individual from his/her limbic system;~* Release endorphins - a release for the internal stress created by the emotion; and~* Self-soothe - a method of quelling and containing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Isometric Exercise
Description: 5-minute protocol for cravings management and affect regulation
Study: NCT01557621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Pop-Based R/R: Phone/Mail Group
Description: Within each county, half of patients will be randomized to a phone/mail group (2 auto-dialer calls and 2 postcards) and the other half of patients will be put in a mail-only group (4 mailings). The following collaborative approaches will be utilized: patient addresses and phone numbers will be updated prior to recall for electronic Flat File Format practices; all notices to parents (auto-dialer calls and mailings) will appear to come both from the local public health department and providers who choose to have their name listed; all bad addresses and phone numbers will be updated by calling the last provider of care. Up to 4 notices will be sent to parents of children who are still not up to date for recommended immunizations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Pop-Based R/R: Mail-Only Group
Description: Parents will receive up to four mailings if their child appears in need of immunizations according to CIIS. The Collaborative method is the same as in the auto-dialer/mail group; however patients in this group will not receive telephone calls.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Practice-based Recall
Description: All practices will receive training on how to conduct practice-based recall using CIIS and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone) in order to assess the effect of these additional interventions.
Study: NCT00642135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mydriasert®
Description: Premature newborns and neonates treated using ophthalmologic insert Mydriasert®
Study: NCT03091192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg by mouth (PO) once daily (QD), with or w/o food, 4 weeks on/2weeks off
Study: NCT04266886

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive usual care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: Receive self-hypnosis guided relaxation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00642135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenylephrine and tropicamide eyedrops
Description: Premature newborns and neonates treated using reference treatment (association of Phenylephrine and tropicamide eyedrops)
Study: NCT00423293

Intervention type: DRUG
Group type: OTHER
Intervention: fluorouracil
Description: 1000 mg/m\^2/day 96-hour continous infusion (M-F) starting on day 1 and again on day 29 of radiation therapy.
Study: NCT04266886

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00423293

Intervention type: DRUG
Group type: OTHER
Intervention: mitomycin C
Description: 10 mg/m\^2 intravenous therapy on day 1 and day 29 of radiation therapy.

Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity-modulated radiation therapy
Description: Prescription dose depends on tumor staging.~T2N0: The primary tumor PTV (planning target volume) (PTVA) receives 50.4 Gy in 28 fractions (fx) at 1.8 Gy/fx. The nodal PTVs receive 42 Gy in 28 fx at 1.5 Gy/fx. PTVA receive 50.4 Gy in 28 fractions at 1.8 Gy/fx. PTV42 receive 42 Gy in 28 fx at 1.5 Gy/fx and will include all nodal regions.~T3N0 or T4N0: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. The nodal PTVs will receive 45 Gy in 30 fx at 1.5 Gy/fx. PTVA will receive 54 Gy in 30 fx at 1.80 Gy/fx. PTV45 will receive 45 Gy in 30 fx electively at 1.5 Gy/fx and will include all nodal regions.~For N+ disease: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. For involved nodes ≤ 3 cm in maximum dimension, the involved nodal PTV will receive 50.4 Gy in 30 fx at 1.68 Gy/fx. For involved nodes \> 3 cm in maximum dimension, the involved nodal PTV will receive 54 Gy in 30 fx at 1.80 Gy/fx.
Study: NCT01208155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, 50 mg x 2, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, 100 mg Batch 1, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, 100 mg Batch 2, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, 100 mg Batch 3, single dose
Study: NCT02357810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Topotecan Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02761460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF 6mg is given for patients Greater than or equal to 45 kg, 3mg is given for those less than 45kg 24-48 hours after chemotherapy
Study: NCT01780129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polydatin Injectable
Description: Dilute two 100mg/5mL vials of HW6 into 500mL 0.9% NaCl injection and administer as i.v. infusion over 2 hours. The drug should be given as early as possible right after the IC Form is signed on Day 1, and once every 24 hours for additional 4 doses.
Study: NCT02007408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracervical block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracervical block + lidocaine spray
Study: NCT03153982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given orally
Study: NCT02826668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: A baseline lumbar ultrasound in a standardized lateral position (by bed markings) will be performed with the midline and L3-L4 interspace marked, and estimated depth to the epidural space recorded. A second lateral lumbar ultrasound will be performed immediately prior to placement at the time of epidural request. The bed position will be standardized with lines drawn down the back, at the flexion of the knee, and heel of the foot. The sonographic measurements will include the midline, the L3-4 interspace, (both marked at the skin surface), and the measured depth to the ligamentum flavum (in centimeters).
Study: NCT02923362

Intervention type: PROCEDURE
Intervention: Laparoscopic Fundoplication
Description: The gastric fundus of the stomach is wrapped or plicated around the lower end of the esophagus and and stitched in place reinforcing the closing function of the lower esophageal sphincter. The hiatus is also narrowed down with sutures or mesh to prevent or treat a concurrent hiatal hernia.

Intervention type: DEVICE
Intervention: LINX Antireflux
Description: The LINX is a flexible band of interlocked titanium beads with a magnetic core. The LINX is placed around the lower esophageal sphincter to help restore the function of the LES by preventing reflux into the esophagus.
Study: NCT02490462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education + Conventional PhysicalTherapy
Description: The education program for parents will be held one day a week for 1 hour, with total duration of 12 weeks. During the parents or legal guardian meetings will be oriented to stimulate the drive to your child or ward during everyday activities such as bathing, dressing, eating, transferring, going to the bathroom. Parents will receive a diary to record the activities in the home environment. The orientation day for parents will take place in different days of the day the child will receive physical therapy, so that the physiotherapist responsible for the training of parents is shrouded in relation to the randomization of the subjects. This program will be associated with conventional physical therapy program that provides for movements based on neurodevelopmental concept.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: The full program will be for 24 weeks, the first step will consist of 12 weeks of training with a frequency of twice a week should total at least 18 Conventional physical therapy interventions and 09 meetings of guidelines for parents. After this step be performed to start new reviews second step further 12 weeks with the same characteristics as the first 12 weeks. The conventional physiotherapy program will consist of functional muscle training focused on the task. Tasks will be individualized based on the results of the evaluations of Gross Motor Function and Inventory Pediatric Evaluation of Disability. The sessions will last 45 minutes carried out 2 times a week, training will have a total duration of 12 weeks.
Study: NCT03495739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDG-17012 Capsule
Description: Dabigatran Etexilate tosylate 150mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran Etexilate Mesylate 150 MG Oral Capsule
Description: Dabigatran Etexilate mesylate 150mg
Study: NCT03934723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention consists of 180 minutes of moderate-vigorous aerobic exercise per week for 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The intervention consists of 180 minutes of moderate-vigorous aerobic exercise per week for 6 weeks.
Study: NCT03089697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-Rephasin® SAL200
Description: A single dose of SAL200 (SAL-1, 3mg/kg) intravenous administration of the study drug, in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of the formulation buffer (placebo), excluding the main ingredient of the study drug in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
Study: NCT00135798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LADR Treatment
Description: PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen; Rebetol (ribavirin (RBV) United States Pharmacopeia (USP)) Capsules:~Treatment was initiated with PEGIFN 0.75 µg/kg/week and RBV 600 mg/day. Dose escalations were performed at weeks 1 (PEGIFN 1.5 µg/kg/week and RBV 800 mg/day), 2 (RBV 1.0 g/day), and 3 (RBV 1.2 g/day for patients who weighed more then 75 kg) based upon patient tolerance and weekly blood counts. Once a patient reached the target RBV dose of 1-1.2 g/day (approximately 10.6 to 13.2 mg/kg/day), no further increases in RBV dose were made. Subsequent doses of PEGIFN and RBV were adjusted based upon adverse events, patient tolerability, and blood counts. If the highest tolerated dose of PEGIFN was \<0.5 ug/kg, PEGIFN was permanently discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LADR Treatment
Description: PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen; Rebetol (ribavirin (RBV) United States Pharmacopeia (USP)) Capsules:~Treatment was initiated with PEGIFN 0.75 µg/kg/week and RBV 600 mg/day. Dose escalations were performed at weeks 1 (PEGIFN 1.5 µg/kg/week and RBV 800 mg/day), 2 (RBV 1.0 g/day), and 3 (RBV 1.2 g/day for patients who weighed more then 75 kg) based upon patient tolerance and weekly blood counts. Once a patient reached the target RBV dose of 1-1.2 g/day (approximately 10.6 to 13.2 mg/kg/day), no further increases in RBV dose were made. Subsequent doses of PEGIFN and RBV were adjusted based upon adverse events, patient tolerability, and blood counts. If the highest tolerated dose of PEGIFN was \<0.5 ug/kg, PEGIFN was permanently discontinued.
Study: NCT02637895

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill matching Vortioxetine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vortioxetine
Description: Immediate Release 10 mg. Vortioxetine Pill
Study: NCT04748458

Intervention type: DEVICE
Intervention: Conical tapered stem
Description: Implantation of conical tapered stem
Study: NCT04322019

Intervention type: OTHER
Intervention: Data record
Description: Data record
Study: NCT01647516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Ozanimod capsules by mouth daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Ozanimod capsules by mouth daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00920127

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AKL1
Description: Each dose of AKL1 or placebo will consist of two capsules which will be swallowed twice daily for 8 weeks.~The morning dose of study medication should be taken at approximately the same time each morning between 7:00 am and 10:00 am and should consist of two 500 mg capsules and then repeated between 7.00 pm and 10 pm.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: AKL1
Description: Each dose of AKL1 or placebo will consist of two capsules which will be swallowed twice daily for 8 weeks.~The morning dose of study medication should be taken at approximately the same time each morning between 7:00 am and 10:00 am and should consist of two 500 mg capsules and then repeated between 7.00 pm and 10 pm.
Study: NCT03586674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipanthyl
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursogal
Description: suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursogal
Description: suspension
Study: NCT03109665

Intervention type: DIAGNOSTIC_TEST
Intervention: SD-OCT Angiography
Description: SD-OCT Angiography

Intervention type: DIAGNOSTIC_TEST
Intervention: SD-OCT
Description: SD-OCT
Study: NCT01178879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth consultation
Description: The consultations are structured as outpatient sessions immediately after discharge. The content of the education deals with the regular treatment, prevention of exacerbation and how to live with the illness. The aim of the counseling is to increase the patient's empowerment and competence to take action. The patients have the consultations for 7 days followed by a telephone call. Each session is organized and individualised according to the patient's wishes and needs for education and counselling.~The equipment consists of a computer with web camera, microphone and measurement equipment. A button to contact to the nurse at the hospital, an alarm button and a volume button. The results are transferred to the hospital by a secure internet line.
Study: NCT03193801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN 3 transcatheter valve, Model 9600TFX
Description: Edwards SAPIEN 3 THV system Model 9600TFX with the associated delivery systems.
Study: NCT00900549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT on
Description: 12 months

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CRT off
Description: 12-month
Study: NCT02188472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penicillin V
Description: Penicillin V: 2 x 330mg tablets should be taken twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim
Description: Trimopan: 2 x 100mg tablets should be taken twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 2 tablets should be taken twice daily
Study: NCT02573558

Intervention type: DRUG
Intervention: Dexmedetomidine

Intervention type: DRUG
Intervention: Propofol
Study: NCT02733354

Intervention type: DEVICE
Intervention: watch viedo
Study: NCT00846677

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D, cholecalciferol
Description: Oral Quick Dissolve Strip, 400 IU once per day for 21 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D, cholecalciferol
Description: Oral Syrup, 400IU per day for 21 days
Study: NCT02659514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: 8 mg oral tablets, administered QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: 8 mg oral tablets, administered QD.
Study: NCT03417232

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: CAF
Description: The design of the flap consisted of two horizontal beveled incisions (3mm in length) and two slightly oblique beveled incisions. The resulting trapezoidal-shaped flap was elevated in the coronal-apical direction. The suture of the flap started with two interrupted periosteal sutures performed at the most apical extension of the vertical releasing incisions; afterwards, it proceeded coronally with other interrupted sutures, each of them directed, from the flap to the adjacent buccal soft tissue, in the apical-coronal direction. The last sling suture allowed for the stabilization of the surgical papillae over the inter-dental connective tissue bed and allowed for a precise adaptation of the flap margin over the underlying convexity of the crown.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF
Description: The design of the flap consisted of two horizontal beveled incisions (3mm in length) and two slightly oblique beveled incisions. The resulting trapezoidal-shaped flap was elevated in the coronal-apical direction. The suture of the flap started with two interrupted periosteal sutures performed at the most apical extension of the vertical releasing incisions; afterwards, it proceeded coronally with other interrupted sutures, each of them directed, from the flap to the adjacent buccal soft tissue, in the apical-coronal direction. The last sling suture allowed for the stabilization of the surgical papillae over the inter-dental connective tissue bed and allowed for a precise adaptation of the flap margin over the underlying convexity of the crown.
Study: NCT04174183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-incision Negative-pressure Therapy - Dry dressing
Description: A Closed-incision Negative-pressure Therapy is applied on one groin incision - A dry dressing is applied on one groin incision .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-incision Negative-pressure Therapy - Dry dressing
Description: A Closed-incision Negative-pressure Therapy is applied on one groin incision - A dry dressing is applied on one groin incision .
Study: NCT00270153

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: enalapril
Description: 5mg enalapril daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg enalapril-matching placebo daily for 6 months
Study: NCT01595464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Skills Groups
Description: Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting